Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
CC transcript
|
|
AGENUS INC (AGEN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
4
| ARMEN GARO H (See Remarks) has filed a Form 4 on AGENUS INC|
Txns:
| Granted 15,305 shares
@ $1.06, valued at
$16.2k
|
|
| 10/06/2023 |
4
| AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Bought 15,001 shares
@ $1.0919, valued at
$16.4k
|
|
| 10/04/2023 |
4
| Wright Timothy (Director) has filed a Form 4 on AGENUS INC|
Txns:
| Granted 6,586 restricted stock units
@ $0 |
|
| 10/04/2023 |
4
| Hirsch Susan B (Director) has filed a Form 4 on AGENUS INC|
Txns:
| Granted 14,928 restricted stock units
@ $0 |
|
| 10/04/2023 |
4
| WIINBERG ULF (Director) has filed a Form 4 on AGENUS INC|
Txns:
| Granted 18,001 restricted stock units
@ $0 |
|
| 08/23/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Financial Statements and Exhibits Interactive Data |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 07/06/2023 |
4
| Hirsch Susan B (Director) has filed a Form 4 on AGENUS INC|
Txns:
| Granted 13,283 restricted stock units
@ $0 |
|
| 07/06/2023 |
4
| WIINBERG ULF (Director) has filed a Form 4 on AGENUS INC|
Txns:
| Granted 16,018 restricted stock units
@ $0 |
|
| 07/06/2023 |
4
| Wright Timothy (Director) has filed a Form 4 on AGENUS INC|
Txns:
| Granted 5,860 restricted stock units
@ $0 |
|
| 05/26/2023 |
4/A
| AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc. |
| 05/26/2023 |
4/A
| AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Disposed of 5,006,397 shares
@ $0 |
|
| 05/26/2023 |
SC 13D/A
| AGENUS INC reports a 62.5% stake in MINK THERAPEUTICS, INC. |
| 05/12/2023 |
4
| AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Bought 22,065 shares
@ $1.509, valued at
$33.3k
Bought 23,361 shares
@ $1.4275, valued at
$33.3k
|
|
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 05/05/2023 |
4
| AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Bought 128,689 shares
@ $1.0789, valued at
$138.8k
Bought 21,473 shares
@ $1.2223, valued at
$26.2k
Bought 100,000 shares
@ $0.9485, valued at
$94.9k
Bought 200 shares
@ $1.25, valued at
$250 |
|
| 05/03/2023 |
4
| AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Disposed of 4,988,273 shares
@ $0 |
|
| 05/03/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/24/2023 |
8-K
| Quarterly results |
| 04/03/2023 |
4
| Hirsch Susan B (Director) has filed a Form 4 on AGENUS INC|
Txns:
| Granted 9,870 restricted stock units
@ $0 |
|
| 04/03/2023 |
4
| WIINBERG ULF (Director) has filed a Form 4 on AGENUS INC|
Txns:
| Granted 11,902 restricted stock units
@ $0 |
|
| 04/03/2023 |
4
| Wright Timothy (Director) has filed a Form 4 on AGENUS INC|
Txns:
| Granted 4,354 restricted stock units
@ $0 |
|
| 03/30/2023 |
8-K
| Quarterly results |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/14/2023 |
8-K
| Quarterly results|
Docs:
|
"Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives Botensilimab plus balstilimab showed overall response rates of 23% in microsatellite stable colorectal cancer , 50% in PD-1 refractory non-small cell lung cancer and in seven additional metastatic, late-line cancers in a total of more than 300 patients Randomized Phase 2 trials in MSS CRC, melanoma, and pancreatic cancers are underway; a confirmatory phase 3 trial in MSS CRC is expected to be launched in 2023 Data demonstrating clinical benefit in MSS CRC, NSCLC, ovarian cancer, and sarcomas were presented in plenary sessions at ESMO GI, SITC, and CTOS in 2022, and in a late-breaking oral session at ASCO GI in January 2023 Existing corporate collaborations have potential to generate up to $2.7B ..." |
|
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 8% stake in Agenus Inc. |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/09/2023 |
4
| Hirsch Susan B (Director) has filed a Form 4 on AGENUS INC|
Txns:
| Granted 100,000 options
@ $2.4, valued at
$240k
|
|
|
|
|